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ABSTRACT:
A cDNA encoding for zebrafish -glutamyl hydrolase (GH) was
cloned and inserted into a pET43.1a vector via SmaI and EcoRI
sites and expressed in Rosetta (DE3) cells as a Nus-His-tag fusion
enzyme (NH-zGH). After induction with isopropyl thiogalactoside,
the enzyme was purified with a Ni-Sepharose column, and approx-
imately 8 mg of pure enzyme was obtained per liter of culture. The
primary sequence of the recombinant zGH was similar to mam-
malian GH. Thrombin digestion of this NH-zGH fusion protein
resulted in zGH with approximately 2-fold higher catalytic activity
compared with the NH-zGH fusion enzyme. This recombinant
zGH is active and exhibits comparable endopeptidase activity
with folate substrate and antifolate drug methotrexate. Use of this
recombinant zGH significantly increased efficiency in folylpoly-
glutamate hydrolysis for folate analysis compared with current
protocols.
Folate is an essential B vitamin and participates in the biosynthesis
and metabolism of nucleic acids, proteins, several amino acids, methyl
groups, many neurotransmitters, and some vitamins. Mammalian cells
are unable to synthesize folates de novo and therefore depend on their
food for the supply of folates. Naturally occurring folates are synthe-
sized as poly--glutamate forms (folylpolyglutamate) but are ab-
sorbed and transported most efficiently as folylmonoglutamates. The
conversion of folylpolyglutamates in dietary food to folylmonogluta-
mates is catalyzed by carboxypeptidase II (EC 3.4.22.12) in mam-
mals. In a recent study, -glutamyl hydrolase (GH, EC 3.4.19.9), a
lysosomal cysteine peptidase, was reported to be the enzyme respon-
sible for hydrolyzing dietary folate in rat small intestine (Shafizadeh
and Halsted, 2007). After entering cells, these folylmonoglutamates
are elongated to folylpolyglutamates by folylpoly--glutamate syn-
thetase (EC 6.3.2.17) for more effective retention and cofactor activ-
ity. As part of a salvage pathway, GH catalyzes the hydrolysis of
Glu--Glu bonds to form folylmonoglutamates, enabling folate co-
factors to be exported from cells and enter circulation again (Suh et
al., 2001). Therefore, folylpoly--glutamate synthetase and GH are
crucial for the maintenance and regulation of intracellular folate
homeostasis. Nevertheless, the mechanism of turnover and control of
cellular folylpolyglutamate levels by GH remain unclear. A better
understanding of this enzyme and an efficient assay system is prereq-
uisite to answer this question.
Consistent with this notion, the activity of GH to hydrolyze the
-glutamyl peptide bonds of folylpolyglutamates has rendered this
enzyme a potential target of antifolate chemotherapy and, at the same
time, a primary component in regulating the intracellular levels of
some antifolate drugs. Antifolate drugs, such as methotrexate, owe
much of their effectiveness to being substrates for both folylpoly--
glutamate synthetase and GH. Removal of -linked glutamate resi-
dues decreases the retention and activity of these drugs. A polymor-
phism resulting in reduced catalytic activity of GH was observed to
be associated with greater accumulation of long-chain methotrexate
polyglutamate forms (Cheng et al., 2004). In contrast, higher GH
activity has been connected to the development of drug resistance
(Rhee et al., 1993). Therefore, alteration to GH availability or
activity seems to have functional and pharmacological consequences
and even to be a potential tumor marker (Schneider and Ryan, 2006).
Having pure and active GH is essential to structural and kinetic
studies of GH and to additional investigation for its role in affecting
antifolate drug efficacy.
The determination of individual folate derivatives in serum of
patients receiving antifolate chemotherapy and in foods is an impor-
tant current protocol. The first step in these determinations is con-
verting folylpolyglutamates to folylmonoglutamates by GH. Cur-
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rently, hog kidney, chicken pancreas, and rat serum/plasma are the
main sources used to provide GH activity (Quinlivan et al., 2006).
However, large amounts of plasma or extract and long incubation
times are often required for an acceptable degree of conversion,
resulting in significant dilution, higher background, and loss of folate
cofactors in samples. Having a pure and concentrated GH will
improve the accuracy of folate determinations.
An efficient animal model for drug safety and efficacy screening is
indispensable, despite the historic progress in the past few decades in
pharmaceutical manufacturing. Zebrafish, a vertebrate, is becoming a
prominent animal model, providing a platform for fast drug screening.
The advantages are its similarity to mammals in many biological
pathways and pathogenesis, abundant offspring, rapid development,
transparent embryo, and easy growth and breeding. Especially impor-
tant for drug discovery is that zebrafish embryos are permeable to
small molecules and drugs during organogenesis, providing easy
access for drug administration and vital dye staining (Kari et al.,
2007). In addition, the external fertilization and development of
embryos prevent the often occurring misinterpretation of experimental
results as a result of maternal supply of folates. Well established tools
of molecular biology for gene manipulation have also significantly
assisted progress with zebrafish. We have started an extensive study
of folate-mediated one-carbon metabolism in zebrafish (Chang et al.,
2006, 2007; Kao et al., 2008). In this study, we cloned the coding
sequence of zebrafish GH (zGH) from a zebrafish cDNA library
and developed an efficient protocol for expression and purification of
the recombinant zGH. To our knowledge, this is the first report for
the cloning, expression, and purification of zGH. We showed that
this recombinant zGH catalyzed the hydrolysis of natural folate
substrates and an antifolate drug with similar efficiency. In addition,
data showing improved efficiency of converting folate-polygluta-
mates to monoglutamates in a folate analytical protocol with high-
performance liquid chromatography (HPLC) by replacing conven-
tional rat serum with the recombinant zGH is discussed.
Materials and Methods
Materials. Polymerase chain reaction (PCR) primers were ordered from
MDBio, Inc. (Taipei, Taiwan). The SMART RACE amplification kit was
purchased from Clontech/Takara Bio Co. (Mountain View, CA). PCR Master
Mix was purchased from ABgene (Epsom, Surrey, UK). Enzymes used for
cloning were purchased from Invitrogen (Carlsbad, CA) and New England
Biolabs (Ipswich, MA). The HPLC Aquasil C18 column and guard columns
were purchased from Thermo Fisher Scientific (Waltham, MA). Nickel-Sepha-
rose (Ni-Sepharose) resin slurry was purchased from GE Healthcare (Little
Chalfont, Buckinghamshire, UK). Rat serum was prepared as described pre-
viously (Wilson and Horne, 1982). All of the fully reduced monoglutamated
folates were gifts from Dr. Moser (Merck Eprova AG, Schaffhausen, Switzer-
land). (6S)-N5-CHO-tetrahydrofolate (Leucovorin) triglutamate was a gift from
Dr. Schirch (Virginia Commonwealth University, Richmond, VA). Methotrex-
ate pentaglutamate was purchased from Schircks Laboratories (Jona, Switzer-
land). All the other chemicals, including folic acid, dihydrofolate, buffers, and
amino acids, were purchased from Sigma-Aldrich (St. Louis, MO).
Fish Care and Preparation of cDNA Libraries. Zebrafish (Danio rerio,
AB strain) were bred and maintained in a 10-h/14-h light/dark diurnal cycle
following the standard procedure described by Westerfield (1995). Embryos
were staged according to Kimmel et al. (1995). Total RNA isolation and cDNA
library construction from zebrafish embryos and tissues were prepared with
RNAzol B reagent (Tel-Test Inc., Friendswood, TX) and the SMART-RACE
cDNA Amplification Kit (Clontech) as described previously (Kao et al., 2008).
Bacterial Strains, Plasmids, and General Cloning Procedures. The
Escherichia coli strain XL1 Blue (recA1, endA1, gyrA96, thi-1, hsdR17(rK
,
mK
), supE44, relA1, lac) was used for the construction of clones. The E.
coli strains Rosetta (DE3) (F recA rk12
 mk12
) containing the T7 RNA
polymerase gene was used for protein expression. The pET43.1a plasmid and
all the E. coli strains for cloning and expression were obtained from Novagen
(Madison, WI). The materials and methods for the general cloning procedures
were as described previously (Kao et al., 2008).
Cloning of zGH Coding Sequences. Primers were designed based on the
zGH cDNAs available in GenBank (GenBank accession number BC066746)
to PCR amplify complete GH coding sequence from zebrafish 5-RACE-
Ready cDNA libraries. The primer sequences were 5-GGGGCATATGAT-
TCACATCTTTCTTTTG-3 (forward) and 5-GGGGCTCGAGATT-
GAAAAAATATGTCTGTTC-3 (reverse) with introduced NdeI and XhoI
restriction enzyme sites (underlined) to simplify the cloning procedures. The
PCR fragments close to 1 kilobase were cloned into the expression vector
pET43.1a between NdeI and XhoI sites, generating zGH/pET43.1a. For
constructing Nus-His-fusion zGH (NH-zGH), PCR with another pair of
primers, 5-GACCCGGGGACCTTTAATAAAAACTAATGAAAG-3 (for-
ward) and 5-GGGAATTCCTAATTGAAAAAATATGTCTG-3 (reverse),
was performed using the previously obtained zGH/pET43.1a plasmid as
template. The restriction enzyme sites for SmaI and EcoRI (underlined),
respectively, were introduced for the convenience of subsequent cloning. The
resulting 900-base pair fragment was cloned into the expression vector
pET43.1a between SmaI and EcoRI, resulting in an open reading frame
encompassing coding sequences of Nus-Tag, His-Tag, and Gly22 to Asn312 of
zGH. Successful cloning was confirmed by restriction enzyme digestion and
DNA sequencing. The resulting constructs were transformed into Rosetta
(DE3) cells for zGH expression and purification.
Expression and Purification of Recombinant zGH. E. coli containing
the desired plasmid, either zGH/pET43.1a or NH-zGH/pET43.1a, was
grown overnight at 37°C in 50 ml of enriched Luria broth (2-YT) containing
100 g/ml ampicillin. This culture was used to inoculate 1 liter of the same
broth and the inoculum continuously grown at 37°C. Recombinant zGH was
induced by adding isopropyl--D-thiogalactopyranoside (IPTG) to a final
concentration of 0.4 mM when the inoculum reached log phase. After 4-h
incubation with vigorous shaking at 27°C, bacteria cultures were centrifuged,
and cell pellets were subjected to protein purification.
For the purification of NH-zGH, cells were resuspended in 20 ml of lysis
buffer (20 mM sodium phosphate, pH 7.4, 0.5 M NaCl, 5 mM 2-mercapto-
ethanol, 1 mM MgCl2, and 10% glycerol) and subjected to cell disruption with
a French press. The cell lysate was treated with DNase I (30 g/ml) at 25°C
for 20 min and pelleted again by centrifugation at 4°C. The supernatant was
mixed with an equal volume of binding buffer (20 mM sodium phosphate, pH
7.4, 0.5 M NaCl, and 20 mM imidazole) before adding to 5 ml of Ni-Sepharose
resin and incubating at 4°C for 2 h. The slurry of cell lysate and Ni-Sepharose
resin was briefly centrifuged; the supernatant containing unbound protein was
discarded; and the Ni-Sepharose resin removed to a column (1.5  5.0 cm).
After a thorough wash with 5 to 10 resin volumes of binding buffer, NH-zGH
was eluted with binding buffer containing 200 mM imidazole. Fractions
containing protein were combined, and NH-zGH was precipitated by 50%
ammonium sulfate, dialyzed in phosphate buffer containing 10% glycerol, and
stored at 20 or 80°C.
To remove the N-terminal Nus-His tag, ammonium sulfate-precipitated
NH-zGH was subjected to a 2-h dialysis in 1 liter of thrombin cleavage buffer
(50 mM Tris, pH 7.4, 150 mM NaCl, 2.5 mM CaCl2, and 0.1% 2-mercapto-
ethanol). The desalted NH-zGH was digested with thrombin in a 1:500 ratio
at room temperature for 20 min followed by a further incubation at 4°C for 6 h.
The digested sample was loaded on an equilibrated Ni-Sepharose column again
as described previously. The zGH in the fraction of flow-through was
collected, and ammonium sulfate was precipitated and dialyzed. Both purified
NH-zGH and zGH were stored at 80°C in the presence of 5 mM 2-mecap-
tolethanol, 20% ammonium sulfate, and 10% glycerol without significant loss
of activity for at least 6 months.
Determination of Stoichiometry for NH-zGH and zGH. Recombinant
NH-zGH and zGH were chromatographed on a Superdex 200 size exclusion
column (0.46  30.0 cm) equilibrated with 20 mM potassium phosphate, pH
7.0, containing 100 mM NaCl and 5 mM 2-mercaptoethanol on an Agilent
Technologies (Santa Clara, CA) 1100 HPLC. The retention times of analyzed
proteins were compared with the protein standards of known molecular weight
and molecular weights obtained by standard curve interpolation.
Measurements of GH Activity. A modified reversed-phase HPLC
method was used to detect GH activity (Patring et al., 2005). GH catalyzes
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the hydrolysis of the -glutamate bond, resulting in folate-mono-Glu. The
progression and rate of reaction were monitored by comparing the peak
retention times and peak areas of 5-CHO-tetrahydrofolate (THF)-Glu1 and
-Glu3 with those of pure corresponding folates of known concentrations.
NH-zGH or zGH at less than 1% of substrate concentrations was used for
the reaction rate measurement. In brief, 0.5 to 250 pmol of purified NH-zGH
(in the volume of 0.5 l) or 5 to 20 l of rat serum was added to 100 l of
reaction mixture containing 50 mM potassium phosphate, pH 6.0, 14 mM
2-mercaptoethanol, 2% ascorbic acid, and 2.5 M 5-formyltetrahydrofolate
triglutamate (5-CHO-THF-Glu3) or methotrexate-Glu5 in a 1.5-ml centrifuge
tube. Tubes were flushed with nitrogen before capping and incubated at 37°C.
After designated incubation times, tubes were boiled for 3 min and immedi-
ately chilled on ice to stop the reaction and precipitate protein simultaneously.
The samples were centrifuged, and the supernatants were filtered and analyzed
on an Aquasil C18 column, 150  4.6 mm, 3 m (Thermo Fisher Scientific),
using an HPLC system (Agilent 1100) with a fluorescence detector. The
mobile phase used was acetonitrile/30 mM phosphate buffer, pH 2.3, under
linear gradient elution conditions and the flow rate 0.4 ml/min. Retention times
and peak areas of pure 5-formyltetrahydrofolate monoglutamate (5-CHO-
THF-Glu1) and 5-CHO-THF-Glu3 of known concentrations were used for peak
identification and standard curves construction. An estimation of the maximum
rate was determined at the earliest time point when approximately 50% of
5-CHO-THF-Glu3 had been converted to the monoglutamate. For kinetic
studies, apparent Km and kcat were determined by performing reactions in the
presence of 10 nM purified zGH and 5-CHO-THF-Glu3 ranging from 10 to
150 M. The initial velocities were determined from the amount of 5-CHO-
THF-Glu1 generated within the first 30 s at each substrate concentration after
the reaction was initiated. The kinetic constants were determined from double-
reciprocal plots of initial velocity versus substrate concentration.
Results
Sequence and Structural Analysis of Recombinant zGH. The
isolated full-length zGH cDNA (EU918170) is 939 base pair and
encodes a protein of 312 amino acids. Currently, GH has been
identified in several mammals, including humans. Substantial simi-
larities of primary structure between zGH and its mammalian coun-
terparts reveal conservation during evolution of this enzyme. A high
level of homology is observed in the primary sequences and more so
for the amino acid residues essential for catalytic activity (Fig. 1). A
53.8% identity between zebrafish and human GH primary sequences
is observed. The residues crucial for catalytic activity—Tyr36, His171,
His220, and Glu222—are conserved in the zebrafish enzyme, as well as
Cys110, the residue mediating nucleophilic attack at the active site
(Schneider and Ryan, 2006). Higher peptide sequence variation is
observed in the postulated signal sequence (from Ile2 to Phe21). This
prediction is based on the comparison with GH of other species with
known signal peptide sequences (Yao et al., 1996a,b). The predicted
sequence patches present in the homodimer interface of mammalian
enzymes also show similarity in zGH, especially the first patch
(Ala54 to Ser60). Two of the consensus Asn-linked glycosylation sites
are also observed in zGH (Yao et al., 1996b). The primary sequence
of zGH was subjected to on-line secondary structure prediction
and compared with human GH (“PredictProtein,” http://www.
predictprotein.org/newwebsite/submit.php; Rost et al., 1996). The
predicted seven helices of zGH strongly resemble those of human
GH, indicating structural similarity between zebrafish and human
enzymes (data not shown).
Expression and Purification of zGH. Initially, full-length
zGH, including the prospective signal peptide, was cloned into
pET43.1a with its start codon adjacent right after the ribosomal
binding site on the vector. However, no significant expression was
observed, despite the completely accurate and in-frame coding se-
quence. All our attempts to solve this problem, including changing
competent cells, culture medium, IPTG concentration, induction time,
and temperatures and cell density, were not successful. No enriched
FIG. 1. Alignment of GH peptide sequences. The
shaded characters indicate amino acids that differ among
compared species. Gaps, indicated by hyphens, are intro-
duced for optimal alignment. The arrowheads indicate the
conserved amino acid residues essential for enzyme activ-
ity. The brackets indicate the conserved sequences resid-
ing at the dimer interface. The boxes indicate the potential
consensus residues for glycosylation. The sequences were
aligned using the ClustalW method (Combet et al., 2000)
with MegAlign/DNAstar sequence analysis software
(DNASTAR, Madison, WI). The GenBank accession
numbers of the aligned sequences are NP_003869 for
human GH, NP_034411 for mouse GH, NP_037092
for rat GH, and EU918170 for recombinant zGH in the
current report.
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protein band at the expected range of molecular weight was observed
in the whole cell extract (data not shown). Significant expression of
recombinant zGH was accomplished only when the coding sequence
of zGH without the signal peptide region was subcloned downstream
of the Nus coding sequence and expressed as a Nus-fusion protein
(Fig. 2).
The recombinant NH-zGH was induced by adding 0.4 mM IPTG
at 27°C for 4 h. The majority of induced NH-zGH remained in
soluble fractions under this condition. The His-tag between Nus and
zGH allowed us to use Ni-Sepharose to greatly simplify the purifi-
cation. The NH-zGH eluted from Ni-Sepharose column was at least
95% pure, judged from SDS-polyacrylamide gel electrophoresis
(PAGE) (Fig. 3). Starting from the harvested cell pellet, we were able
to obtain 8 mg of active NH-zGH from 1 liter of culture cells in 5 h
with good yield and purity.
To exclude the possible interference as a result of peptide fusion,
we removed the N-terminal Nus peptide and His-tag by thrombin
digestion of the NH-zGH fusion protein combined with a second run
of Ni-Sepharose column purification. The digestion efficiency and
recovery rate were approximately 60% under the conditions used,
judging from SDS-PAGE and the quantity of obtained thrombin
digested zGH. Approximately 1.5 mg of thrombin-digested zGH
was obtained from 8 mg of purified NH-zGH protein.
Structure and Activity of zGH. Recombinant NH-zGH and
zGH appeared on SDS-PAGE in the ranges of their estimated size of
92 and 33 kDa, respectively (Fig. 3). Unexpectedly, the retention
volumes during chromatography on a Superdex 200 column showed
that NH-zGH and zGH had Stokes radii close to globular proteins
of 400 and 60 kDa, respectively (Fig. 4). These results suggest that
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FIG. 3. SDS-PAGE of zGH at each step of purification. Lane 1, uninduced cell
lysate; lane 2, IPTG-induced cell lysate; lane 3, fraction flow through from Ni-
Sepharose; lane 4, NH-zGH eluted from Ni-Sepharose; lane 5, ammonium sulfate
precipitated NH-zGH after elution from Ni-Sepharose; lane 6, thrombin-digested
NH-zGH before fractionation on the second round of Ni-Sepharose; lane 7,
Ni-Sepharose flow-through of thrombin digested NH-zGH; lane 8, fraction eluted
from the second round Ni-Sepharose; M, molecular weight marker. The upper and
lower arrows indicate NH-zGH and zGH, respectively.
FIG. 2. Map of plasmid pET43.1a/NH-zGH. The construction of this plasmid is
described in detail under Materials and Methods. The crossed and shaded areas
represent the Nus peptide and zGH without the signal peptide, respectively.








































FIG. 4. Size-exclusion chromatographic profiles showing quaternary structures of
recombinant zGH. Approximately 50 g of recombinant zebrafish NH-zGH (A),
NH-zGH thrombin digestion mixture (B), and zGH cleaved from NH-zGH and
purified by a second Ni-Sepharose chromatography (C) were analyzed on Superdex
200 (0.46  30.0 cm) and compared with molecular mass standard markers (D).
Peak 1, NH-zGH; peak 2, Nus-His-tag; peak 3, zGH; peak 4, apo-ferritin (443
kDa); peak 5, -amylase (200 kDa); peak 6, alcohol dehydrogenase (150 kDa); peak
7, albumin (66 kDa); peak 8, carbonic anhydrase (29 kDa); peak 9, ribonuclease A
(14 kDa). X, molecule with unknown identity. The inset shows the plot of log M
(molecular mass of standard markers) versus elution volume (closed circle) and
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whereas NH-zGH is a tetramer (Eisele et al., 2006). It seems that the
presence of the N-terminal Nus and His-tag interferes with the qua-
ternary structure of zGH.
zGH converts folate-polyglutamates to folate-monoglutamates.
This activity was monitored by the conversion of 5-CHO-THF-Glu3
to 5-CHO-THF-Glu1 with HPLC. Shown in Fig. 5A are the chromato-
grams of 5-CHO-THF-Glu3 and 5-CHO-THF-Glu1 present in reaction
mixtures after incubation for 5 min on adding various amounts of
NH-zGH or rat serum to initiate the reactions. Judging from the peak
areas corresponding to substrate and product, we found that NH-
zGH, 0.1 g (equivalent to 10 nM) was sufficient to convert more
than 60% of 5-CHO-THF-Glu3 (2.5 M) to 5-CHO-THF-Glu1 at
37°C in 5 min. The better efficiency of deconjugation mediated by
NH-zGH than by rat serum was also observed in the experiment
performed in a time-dependent manner (Fig. 5B). The rate of product
formation catalyzed by recombinant NH-zGH in 2 min was 65
nmol/nmol protein/min. Conversion of all the substrate reached ap-
proximately 80% at 20 min and was completed in 2 h using NH-
zGH. On the other hand, less than 2 and 30% of 5-CHO-THF-Glu3
was deconjugated when rat serum was added in the volume ratio of
1:10 (serum/sample) in 5 and 20 min, respectively. More than 2 h was
required to convert 80% of substrate with rat serum. No significant
loss of product was observed (2.4 M) at the end of 2-h incubation
with NH-zGH, whereas only 80% of the product was detected in the
rat serum sample. Methotrexate-Glu5, an antifolate drug commonly
used in regimens for chemotherapy, was also a substrate of NH-zGH
and zGH with comparable efficiency to 5-CHO-THF-Glu3 (Fig. 5C).
The presence of only methotrexate-Glu5 and methotrexate-Glu1 dur-
ing hydrolysis suggests that zGH is most likely an endopeptidase, as
observed with rat GH (Yao et al., 1996b).
An approximately 2-fold increase was observed for the catalytic
activity of zGH on the removal of the N-terminal Nus peptide and
His-tag compared with NH-zGH. The 5-CHO-THF-Glu1 generated
was almost doubled when the same molecular concentration of NH-
zGH and zGH were used (Fig. 6). The rates of product formation
in the presence of 1.6 M 5-CHO-THF-Glu3 and 3 nM enzymes in 5
min were 20 and 38 min1 for NH-zGH and zGH with approxi-
mately 55 and 95% of product formed, respectively. These results
suggest interference in enzyme activity as a result of the presence of
the N-terminal Nus peptide and His-tag. No significant difference in
the activities was observed when the catalytic reactions were per-
formed at either pH 4 or 6, although slightly higher activity was
observed in acidic condition. Catalytic efficiencies of both NH-zGH
and zGH were lowered to 65% when the reaction mixtures were
performed at pH 12 (data not shown). The estimated apparent kcat and
Km of zGH for 5-CHO-THF-Glu3, obtained from the average of
three independent repeats, are 87.6 min1 and 57.0 M, respectively
(Table 1).
Discussion
In this study, we report the cloning, characterization, and signifi-
cance of zGH and NH-zGH fusion proteins. The purposes for
obtaining pure and active zGH are 2-fold. First, it enables detailed
studies for the properties of zGH and its role in regulating the
intracellular availability of folates and some antifolate drug. This will
help not only to advance our knowledge in antifolate drug mecha-
nisms and development but also to evaluate the feasibility of using
zebrafish as a model for antifolate drug discovery. Second, it im-
proves the efficiency of the critical step of folylpolyglutamate hydro-
lysis for folate measurements.
To our knowledge, this is the first report for the cloning and
purification of zGH. This recombinant zGH expressed and purified
from E. coli was active, suggesting that glycosylation is not essential
for zGH catalytic activity. This is in agreement with a previous
observation with human enzyme (Yao et al., 1996b). However, we
could not exclude the possibility that glycosylation is important for
the regulation of enzyme stability or function. The Km of recombinant
zGH is comparable with that of human enzyme. However, the Vmax
is approximately 35-fold higher than that of human GH (Chave et al.,
1999). Several factors might have contributed to the difference. First,
to avoid potential product inhibition, the initial rate of reaction cata-
lyzed by zGH was determined for the first 30 s after adding enzyme
to initialize the reaction. That was when less than 2% of substrate was
converted to product. Human enzyme was measured when less than
15% of substrate was converted to product. Second, different sub-
strates used in the assays for zebrafish and human enzymes might also
affect the catalytic efficiency of the enzymes. What we used in the
assay was 5-CHO-THF-Glu3, whereas it was 4-NH2-10-CH3 PteGlu2
for human enzyme. Nevertheless, we could not exclude the possible
fundamental differences reside in these enzymes as a result of differ-
ent species, although we think it is less likely.
It was unexpected that our initial attempt to overexpress zGH
without the Nus-expression partner was not successful. We had care-
fully examined the coding sequence for accuracy and codon usage and
found several rarely used codons in E. coli. However, the use of the
Rosetta strain for expression should have overcome this potential
problem (Chang et al., 2007). We also tested for inclusion bodies and
culture broth with SDS-PAGE for the possibility of aggregation or
export of expressed zGH because secretion of this protein had been
reported in mammalian tumor cell lines (Gourdon et al., 2008).
However, no enriched protein band was found in these fractions.
Although we still have no confirmed answer for this result, several
possibilities might help explain this observation. It is possible that the
change of enzyme structure caused by the presence of Nus-His-Tag
expression partner had altered the quaternary structure and the overall
conformation, rendering this recombinant NH-zGH less susceptible
to protease degradation. This hypothesized change in protein confor-
mation might also contribute to the observed decreased activity. An
additional possibility is the lack of an endothelial reticulum system in
E. coli. The presence of a leader sequence on the N-terminal of zGH
implies an endothelial reticulum-associated expression and/or or-
ganelle location for this enzyme. It has been suggested that the signal
sequence must be removed for efficient expression in an E. coli
system (Gourdon et al., 2008).
FIG. 5. HPLC chromatograms showing the concentration and time dependence of 5-CHO-THF-Glu3 and methotrexate-Glu5 hydrolysis. A, 5-CHO-THF-Glu1 generated in
hydrolysis reactions catalyzed by recombinant NH-zGH (left) and rat serum (right) was analyzed by HPLC on a C18 reversed-phase column. The purified NH-zGH or
rat serum of indicated amounts was incubated with 2.5 M 5-CHO-THF-Glu3 at 37°C for 5 min before stopping the reaction and loading on column. The number on the
top of the peak represents the peak area. Peak A, 5-CHO-THF-Glu3; peak B, 5-CHO-THF-Glu1; peak C, 2-mercaptoethanol; peak D, 5-CHO-THF-Glu1 standard; peak E,
10-CHO-THF-Glu1; peak F, THF-Glu1. B, the concentrations of 5-CHO-THF-Glu1 generated in the hydrolysis reactions were plotted against the reaction time.
5-CHO-THF-Glu3 (2.5 M) was incubated with 0.1 g of NH-zGH (dotted line) or rat serum of 1:10 ratio (solid line) at 37°C for indicated time. The concentrations of
5-CHO-THF-Glu1 in the reaction mixtures were calculated by a linear interpolation of the peak areas of 5-CHO-THF-Glu1 in the HPLC chromatograms from a standard
curve constructed with 5-CHO-THF-Glu1 of known concentrations (inset). C, methotrexate-Glu5, instead of 5-CHO-THF-Glu3, was used to examine the catalytic activity
of NH-zGH with HPLC using the condition as described for 5-CHO-THF-Glu3. Peak A, methotrexate (MTX)-Glu5; peak B, MTX-Glu1. The concentrations of MTX-Glu5
(dotted line) and MTX-Glu1 (solid line) generated in the hydrolysis reactions were plotted against the reaction time (inset).
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Adding purified NH-zGH to a deconjugation reaction has in-
creased the hydrolysis efficiency significantly. A 1:5 to 1:10 ratio
between mammalian serum and biological sample is commonly used
for folate deconjugation in most of the folate measurement assays
used currently. Incubation at 37°C for at least 4 h is usually required
for complete hydrolysis. However, this long incubation time has been
reported to be detrimental to folates and therefore decreases accuracy
significantly (Quinlivan et al., 2006). The incubation time required to
reach 80% conversion with purified NH-zGH was less than 15% of
that when rat serum was used. Besides, the dilution effect caused by
the volume of added enzyme (0.5 l) was negligible. We even needed
to dilute the purified enzyme before adding to the reaction mixture.
This high efficiency allows a wide range for the amount of enzyme
added without affecting folate concentrations in the samples. For
example, a second boost with more purified enzyme after the first
5-min incubation might significantly reduce the time needed for
complete conversion. In addition, we used NH-zGH in most of our
assays because small amounts of this fusion enzyme had provided
sufficient activity for our experiments. Nevertheless, using thrombin-
digested zGH is expected to improve the hydrolysis efficiency and
also decrease the incubation time.
There are still unanswered questions remaining about zGH. It is
important to investigate whether GH is the enzyme responsible for
hydrolyzing folylpolyglutamates in zebrafish intestines because that
will affect the absorbance of potential antifolate drugs to be tested in
zebrafish. In addition, comparable catalytic efficiencies of zGH at
both neutral and acidic environments raise the question whether this
enzyme resides only in lysosomes. The enzyme purified in this study
can be used to make an antibody that will help answer the above
questions. Using the zebrafish model for drug discovery is foreseen to
significantly speed up the translation of drug or treatments from bench
research to bedside reality by revolutionizing the cell-based assays to
embryo-based screening (Kari et al., 2007). In previous studies, we
have shown that zebrafish folate enzymes are comparable with their
human and mammalian counterparts for their catalytic and structural
properties, as well as susceptibility to antifolate compounds (Chang et
al., 2006, 2007; Kao et al., 2008). This purified recombinant zGH
will allow for further investigation to unravel the role of this key
enzyme in regulating the intracellular availability of folates and anti-
folate drugs and to use zebrafish as an in vivo model for folate-related
studies and antifolate drug discovery.
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FIG. 6. HPLC chromatograms showing the higher catalytic activity observed with
thrombin-digested zGH than with NH-zGH fusion enzyme for 5-CHO-THF-Glu3
hydrolysis. 5-CHO-THF-Glu3 (1.6 M) was incubated with buffer only (top), 3 nM
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